RGBP — Regen BioPharma Cashflow Statement
0.000.00%
- $0.73m
- $1.77m
- $0.24m
Annual cashflow statement for Regen BioPharma, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 3.41 | -6.77 | 2.44 | 1.16 | -0.668 |
| Non-Cash Items | 0.616 | 0.556 | 0.118 | 0.598 | 0.167 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -4.01 | 5.08 | -3.17 | -1.93 | -0.25 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 0.019 | -1.13 | -0.607 | -0.174 | -0.752 |
| Other Investing Cash Flow Items | 0 | 0.495 | 0.025 | — | — |
| Sale/Maturity of Investment | |||||
| Cash from Investing Activities | 0 | 0.495 | 0.025 | — | — |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -0.026 | 1.36 | -0.094 | 0.244 | 0.631 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.008 | 0.727 | -0.676 | 0.07 | -0.12 |